Drug intelligence / Profile preview

SOL-004

Development stage: Preclinical
Lead developer: Soley Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SOL-004 is a preclinical-stage oral small molecule therapeutic being developed by Soley Therapeutics for the treatment of oncology. The compound was discovered using Soley's proprietary AI-driven platform, which utilizes high-throughput screening and computational modeling to identify novel drug candidates. As of 2024, the specific molecular target and mechanism of action for SOL-004 have not been publicly disclosed by the developer. The program is currently undergoing preclinical evaluation to support potential future clinical development.

Beyond the preview

Go deeper on SOL-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOL-004.

Explore the full profile